Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 09, 2021 16:30 ET | Source: IN8bio, Inc

IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer

NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
November 16, 2021 07:00 ET | Source: IN8bio, Inc

IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer

NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies...
November 11, 2021 07:00 ET | Source: IN8bio, Inc

IN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpoint Inhibitors in Solid Tumors

NEW YORK, Nov. 11, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell...
November 10, 2021 16:15 ET | Source: IN8bio, Inc

IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Closed initial public offering raising net proceeds after expenses of $32.3 million.Added two new independent Directors and increased diversity across our Board of Directors.Completed patient dosing...
November 04, 2021 08:00 ET | Source: IN8bio, Inc

IN8bio to Present at Scientific Conferences in November: PEGS Europe, SITC and SNO

NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell...
October 27, 2021 07:00 ET | Source: IN8bio, Inc

IN8bio’s Announces Peer-Reviewed Publication of Preclinical Results Using Proprietary MGMT-modified Gamma-Delta T Cells (INB-200) with Temozolomide in Mouse Models of Glioblastoma Multiforme

Concurrent dosing of MGMT-modified gamma-delta T cells with Temozolomide (TMZ) demonstrated a significant survival benefit across multiple models of high-grade glioma MGMT-modified gamma-delta T...
October 04, 2021 16:15 ET | Source: IN8bio, Inc

IN8bio to Present at BioFuture 2021 and Advanced Therapies Congress & Expo 2021

NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell...
September 10, 2021 16:15 ET | Source: IN8bio, Inc

IN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update

First cohort dosing completed in Phase 1 clinical trials of INB-200 and INB-100Data presentations made at ASCO and AACR$40M initial public offering (IPO) in August 2021 to fund continuing operations ...
August 30, 2021 07:00 ET | Source: IN8bio, Inc

IN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment Conference

NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell...
August 11, 2021 08:00 ET | Source: IN8bio, Inc

IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

The first cohort has completed dosing with IN8bio’s donor derived allogeneic gamma delta T-cell product candidate, INB-100, with no severe adverse infusion reactions or dose limiting toxicities (DLTs)...